🔗 Visit the ClinicalTrials.gov page for NCT00330161
| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | Drug resistance in metastatic castration-resistant prostate cancer. | Nat Rev Clin Oncol | 2010 | 1.86 |
| 2 | Novel targeted therapeutics for metastatic castration-resistant prostate cancer. | Cancer Lett | 2009 | 1.04 |
| 3 | Targeting Histone Deacetylases in Diseases: Where Are We? | Antioxid Redox Signal | 2014 | 0.88 |
| 4 | Recent developments in prostate cancer biomarker research: therapeutic implications. | Br J Clin Pharmacol | 2011 | 0.86 |
| 5 | Emerging molecularly targeted therapies in castration refractory prostate cancer. | Prostate Cancer | 2013 | 0.83 |
| 6 | Histone deacetylase inhibitors in castration-resistant prostate cancer: molecular mechanism of action and recent clinical trials. | Ther Adv Urol | 2015 | 0.78 |
| 7 | Epigenetic modulators as therapeutic targets in prostate cancer. | Clin Epigenetics | 2016 | 0.76 |